Kalaris Therapeutics
KLRS
84 hedge funds and large institutions have $502M invested in Kalaris Therapeutics in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 26 increasing their positions, 25 reducing their positions, and 11 closing their positions.
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
12% more funds holding
Funds holding: 75 → 84 (+9)
4% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 25
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
0.02% less ownership
Funds ownership: 1.78% → 1.77% (-0.02%)
16% less capital invested
Capital invested by funds: $600M → $502M (-$98.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lido Advisors
Los Angeles,
California
|
+$9.42M |
| 2 |
JP Morgan Chase
New York
|
+$6.87M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$5.52M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$5.26M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$14M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.5M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$8.07M |
| 4 |
Goldman Sachs
New York
|
-$4.52M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$3.58M |
KLRS Hedge Fund Activity: Q2 2021 in Review
84 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q2 2021, worth a combined $502M — down 16% from $600M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new KLRS positions and 11 closed out — a net gain of 9 holders — while 26 added to existing stakes and 25 trimmed.
The largest buyer was Lido Advisors, opening a new position worth an estimated $9.42M. The largest seller was BlackRock, cutting an estimated $14M.
- 84 institutional investors held Kalaris Therapeutics (KLRS) as of Q2 2021, up from 75 in Q1 2021.
- Funds reported $502M of Kalaris Therapeutics stock for Q2 2021, down 16% quarter-over-quarter.
- 20 funds opened new Kalaris Therapeutics positions in Q2 2021 and 11 closed out, a net change of +9 holders.
- The largest Kalaris Therapeutics buyer in Q2 2021 was Lido Advisors, an estimated $9.42M added.
- The largest Kalaris Therapeutics seller in Q2 2021 was BlackRock, an estimated $14M sold.
Based on aggregated 13F filings for Q2 2021.